|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Crizotinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of non-small cell lung cancers (NSLCL) and lymphomas expressing activating translocations or mutations of oncogenic tyrosine kinases (in particular ALK and ROS1).
|
31143519 |
2019 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
|
31177400 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Vaccination with ALK DNA led to protection against lymphoma growth in a murine model.
|
29642597 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinically, cutaneous ALK+ ALCL can be divided into primary (cutaneous forms) and the much more common, secondary dissemination by a systemic lymphoma.
|
29905579 |
2018 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings indicate strong and durable activity of crizotinib in ALK-positive lymphomas and IMTs.
|
29352732 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
BI-ALCL is an anaplastic lymphoma kinase-negative T-cell lymphoma that has a distinctively different clinical course than other breast lymphomas or ALCLs.
|
28625797 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas.
|
28485010 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, combining measurements of sweyjawbu expression and the ratio of the 5' and 3' portions of the ALK transcript provided even more accurate identification of ALK rearrangement-positive lymphomas.
|
27974674 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL) is a rare lymphoma subtype.
|
28693234 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Routine staining of ALK is therefore of no additional benefit for the workup of known early stage MF; however, its use may be beneficial in the initial workup of unspecified large cell lymphomas of the skin.
|
28426485 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, aberrantly expressed ALK is involved in the pathogenesis of diverse malignancies, including distinct types of lymphoma, lung carcinoma, and neuroblastoma.
|
27879258 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, all cases showed copy number gain of the rearranged <i>ALK</i> gene, which is never observed in <i>NPM1-ALK</i>-positive lymphomas.
|
28659337 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed a specific synergistic effect of combining ALK inhibitors with an mTOR inhibitor (temsirolimus), in ALK+ lymphoma cells.
|
27662658 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, antagonizing SUMOylation by the SENP1 protease decreased the accumulation of NPM-ALK and suppressed lymphoma cell viability, proliferation, and anchorage-independent colony formation.
|
26476082 |
2015 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The discovery of anaplastic lymphoma kinase (ALK) has allowed the definition of a distinct entity within the clinically and pathologically heterogeneous group of CD30+ lymphomas.
|
25961700 |
2015 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas ALK-fusion proteins are common in lymphoma and lung cancer, there are few reports of ALK rearrangements in NB indicating that ALK mainly exerts its oncogenic capacity via activating mutations and/or overexpression in this tumor type.
|
25251827 |
2015 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our data argue against PDGFRB activation in association with ALK gene aberrations in metastatic NSCLC and thus seem to imply differential pathobiological roles of ALK alterations in lung cancer and lymphoma, possibly depending on different fusion partner genes.
|
24750504 |
2014 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Once a diagnosis of lymphoma is established, it is important to exclude systemic anaplastic lymphoma kinase-negative ALCL involving the breast, primary cutaneous ALCL, and other CD30(+) lymphoproliferative disorders.
|
24878027 |
2014 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene-expression profiles on 372 PTCL cases were analyzed and robust molecular classifiers and oncogenic pathways that reflect the pathobiology of tumor cells and their microenvironment were identified for major PTCL-entities, including 114 angioimmunoblastic T-cell lymphoma (AITL), 31 anaplastic lymphoma kinase (ALK)-positive and 48 ALK-negative anaplastic large cell lymphoma, 14 adult T-cell leukemia/lymphoma and 44 extranodal NK/T-cell lymphoma that were further separated into NK-cell and gdT-cell lymphomas.
|
24632715 |
2014 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Consequently, STAT3 inhibition provides a possible therapeutic target also for lymphomas with SQSTM1-ALK variant translocation.
|
23588372 |
2013 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We tested the hypothesis that iNOS is deregulated in NPM-ALK(+) T-cell lymphoma and promotes the survival of this lymphoma.
|
23338972 |
2013 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
|
23064464 |
2012 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, recent evidence that aberrant ALK activity is also involved in an expanding number of tumor types, such as other lymphomas, inflammatory myofibroblastic tumor, neuroblastomas and some carcinomas, including non-small cell lung carcinomas, is boosting research progress in ALK-targeted therapies.
|
22998583 |
2012 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
More recently, however, a small number of B-lineage lymphomas have been reported to express ALK fusion genes.
|
21855232 |
2011 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These findings represent the first recurrent translocation reported in ALK-negative ALCL and highlight the utility of massively parallel genomic sequencing to discover novel translocations in lymphoma and other cancers.
|
21030553 |
2011 |